• Labor party win sparks a rally in ASX aged care stocks
  • The new government plans to boost aged care as well as primary care
  • Analytica was the best performing health stock this week

The ALP election win sparked a mini rally in ASX-listed aged care stocks on the first day of trading this week.

Estia Healthcare (ASX:EHE), one of Australia’s larger aged care operators with 68 homes across the country, rose more than 8% on Monday.

As part of its election campaign, Labor has promised an additional $2.5 billion in aged care funding.

That’s an addition to the $18.8 billion, five-year aged care reform program already announced in this year’s Federal Budget.

The new plan would require every aged care facility in the country to have a registered nurse on site at all hours, as well as setting higher meal standards for residents.

In primary healthcare, the Albanese government has also pledged an extra $970 million, including $750 million for the “Strengthening Medicare” taskforce fund.

The taskforce is expected to deliver improved patient access to General Practice, including after-hours GP access, and greater patient affordability.

The Medicare reimbursement program has already received around $31 billion in the 2022-23 Fed Budget, a $7.3bn increase from the previous year – reflecting the increased use of doctors and telehealth during the pandemic.

Former Treasurer Josh Frydenberg noted that telehealth has been the most significant reform to Medicare since its creation, and was “the key landmark reform” within the government’s primary healthcare 10-year plan.

Since March 2020, more than 100 million telehealth services have been delivered to 17 million people in Australia.

Meanwhile the new PM is yet to announce his full cabinet,  but the most obvious choice for the next Federal Health Minister role is Mark Butler.

Butler has been the Shadow Minister for Health and Ageing portfolio since January 2021, after spending five years as a climate spokersperson prior to that.
 

Significant  ASX healthcare movements

CODE COMPANY PRICE 1 WEEK RETURN % 1 MONTH RETURN % 1 YEAR RETURN % MARKET CAP
ALT Analytica Limited 0.0015 50% 0% -40% $6,920,701.69
IMU Imugene Limited 0.205 24% -9% -49% $1,199,003,534.24
CTE Cryosite Limited 0.735 23% 25% 104% $35,875,028.81
ADR Adherium Ltd 0.011 22% 10% -35% $24,290,762.01
ADO Anteotech Ltd 0.1075 14% -17% -66% $198,752,480.20
MEB Medibio Limited 0.004 14% -11% -47% $8,389,465.43
ONE Oneview Healthcare 0.245 14% 9% -26% $127,044,628.24
CDX Cardiex Limited 0.35 13% -5% -49% $38,483,795.00
CPH Creso Pharma Ltd 0.056 12% -7% -64% $72,592,380.11
M7T Mach7 Tech Limited 0.62 12% -15% -42% $142,101,498.56
BDX Bcaldiagnostics 0.1 11% -5% 0% $13,209,471.00
IIQ Inoviq Ltd 0.565 11% -16% -77% $51,990,566.63
IDT IDT Australia Ltd 0.155 11% -6% -47% $38,563,487.52
SHG Singular Health 0.16 10% -18% -43% $10,446,251.04
PTX Prescient Ltd 0.165 10% 27% 57% $107,916,030.59
CHM Chimeric Therapeutic 0.125 9% -7% -55% $35,075,244.84
CYP Cynata Therapeutics 0.38 9% -3% -37% $54,445,105.72
TD1 Tali Digital Limited 0.0065 8% -41% -81% $7,961,145.83
ARX Aroa Biosurgery 0.85 6% -3% -28% $287,888,334.72
DVL Dorsavi Ltd 0.018 6% -14% -38% $6,369,863.13
CGS Cogstate Ltd 1.745 6% -22% 109% $303,336,246.50
RSH Respiri Limited 0.038 6% -36% -60% $28,879,861.15
UBI Universal Biosensors 0.49 5% -34% -27% $91,071,748.88
VLS Vita Life Sciences.. 1.83 5% -13% 66% $97,241,829.96
BWX BWX Limited 1.395 4% -28% -74% $223,527,784.27
SDI SDI Limited 0.845 4% 3% -1% $101,035,700.50
AHC Austco Healthcare 0.1 4% -20% 2% $28,708,566.90
KZA Kazia Therapeutics 0.78 4% -28% -34% $105,775,127.14
IRX Inhalerx Limited 0.085 4% -26% -7% $14,319,691.35
HCT Holista CollTech Ltd 0.03 3% -25% -43% $7,434,425.35
DXB Dimerix Ltd 0.15 3% -3% -39% $48,131,049.90
AC8 Auscann Grp Hlgs Ltd 0.061 3% -9% -45% $26,873,373.71
PBP Probiotec Limited 2.29 3% -5% 13% $186,230,599.74
CYC Cyclopharm Limited 1.35 3% -11% -46% $126,056,011.05
ICR Intelicare Holdings 0.077 3% -23% -70% $6,651,280.33
MDC Medlab Clinical Ltd 0.079 3% -25% -59% $26,689,702.34
IMC Immuron Limited 0.1025 3% -11% -38% $23,349,330.47
TLX Telix Pharmaceutical 4.23 2% -5% 6% $1,323,920,496.00
MVF Monash IVF Group Ltd 1.075 2% -13% 26% $418,857,453.00
TRP Tissue Repair 0.27 2% -23% 0% $12,630,695.85
BNO Bionomics Limited 0.065 2% -2% -68% $87,967,798.36
CAJ Capitol Health 0.335 2% 0% -7% $349,142,866.52
IMM Immutep Ltd 0.385 1% 18% -32% $333,502,328.78
PAR Paradigm Bio. 1.125 1% -18% -52% $261,735,164.25
RHY Rhythm Biosciences 1.18 1% -16% 10% $256,897,694.40
GSS Genetic Signatures 1.295 0% -3% 9% $185,684,864.82
BXN Bioxyne Ltd 0.014 0% -18% -36% $8,962,035.57
AMT Allegra Orthopaedics 0.18 0% -5% -28% $18,802,656.54
RNO Rhinomed Ltd 0.175 0% -15% 10% $50,000,946.45
TSN The Sust Nutri Grp 0.14 0% -13% -70% $16,884,893.90
ATX Amplia Therapeutics 0.12 0% -8% -46% $23,262,480.12
SCU Stemcell United Ltd 0.014 0% 0% -22% $14,696,980.89
IVX Invion Ltd 0.012 0% -17% 20% $76,998,163.73
ICS ICSGlobal Limited 0.575313 0% 0% -1% $6,054,604.94
FFC Farmaforce Ltd 0.035 0% 0% -46% $4,573,834.30
AVE Avecho Biotech Ltd 0.016 0% -16% 0% $29,405,000.42
PIQ Proteomics Int Lab 0.97 0% -13% -12% $107,819,992.50
EZZ EZZ Life Science 0.36 0% -1% -26% $4,593,600.00
PAB Patrys Limited 0.021 0% -9% -22% $43,196,994.90
OPT Opthea Limited 1.29 0% 31% -12% $475,118,028.00
OVN Oventus Medical Ltd 0.021 0% -45% -83% $4,834,530.70
GTG Genetic Technologies 0.0035 0% -22% -59% $27,701,895.43
OSX Osteopore Limited 0.175 0% -13% -65% $20,521,941.65
PAL Palla Pharma Ltd 0.295 0% 0% -24% $47,764,383.09
OSP Osprey Med Inc 0.2 0% -20% -88% $5,131,708.40
IBX Imagion Biosys Ltd 0.042 0% -26% -58% $45,969,959.89
LCT Living Cell Tech. 0.005 0% -38% -52% $5,141,818.62
DOC Doctor Care Anywhere 0.215 0% -20% -73% $48,852,323.65
NXS Next Science Limited 0.84 -1% 0% -53% $176,690,378.76
SOM SomnoMed Limited 1.47 -1% -24% -31% $121,656,193.05
VHT Volpara Health Tech 0.72 -1% -18% -41% $181,393,258.32
PXS Pharmaxis Ltd 0.085 -1% -15% 4% $46,109,545.69
BOT Botanix Pharma Ltd 0.08 -1% -1% 5% $77,851,365.92
VTI Vision Tech Inc 0.39 -1% -20% -68% $9,371,918.40
HGV Hygrovest Limited 0.063 -2% 0% -20% $14,487,101.06
EXL Elixinol Wellness 0.047 -2% -15% -68% $14,864,481.84
CBL Control Bionics 0.235 -2% -36% -63% $11,827,762.91
BIT Biotron Limited 0.092 -2% 19% 70% $63,173,944.17
ZLD Zelira Therapeutics 1.35 -2% -39% -83% $13,024,877.76
IPD Impedimed Limited 0.089 -2% -32% -29% $158,231,296.42
RGS Regeneus Ltd 0.044 -2% -23% -54% $13,483,224.22
RAP Resapp Health Ltd 0.11 -2% 0% 100% $94,511,678.47
NC6 Nanollose Limited 0.085 -2% -14% -6% $12,655,341.28
MEM Memphasys Ltd 0.039 -3% -35% -25% $30,894,955.14
RCE Recce Pharmaceutical 0.775 -3% -13% -25% $135,266,831.43
OCC Orthocell Limited 0.37 -3% -12% -26% $72,937,327.81
ACR Acrux Limited 0.071 -3% -15% -49% $20,214,165.69
HXL Hexima 0.32 -3% 0% 88% $51,116,400.32
CAN Cann Group Ltd 0.32 -3% -22% -29% $115,210,763.25
VBS Vectus Biosystems 1.14 -3% -12% 18% $39,711,248.50
1AD Adalta Limited 0.057 -3% -20% -57% $17,908,530.52
ANP Antisense Therapeut. 0.099 -3% -12% -53% $65,541,809.84
NTI Neurotech Intl 0.056 -3% 12% -3% $39,071,151.06
ALC Alcidion Group Ltd 0.14 -3% -30% -60% $177,529,667.42
AT1 Atomo Diagnostics 0.083 -3% -28% -50% $47,383,952.25
OIL Optiscan Imaging 0.135 -4% -7% -65% $83,590,056.27
RAC Race Oncology Ltd 1.73 -4% -28% -47% $279,159,618.50
LBT LBT Innovations 0.082 -5% -1% 4% $26,231,926.61
RAD Radiopharm 0.195 -5% -24% 0% $23,125,666.40
RAD Radiopharm 0.195 -5% -24% 0% $23,125,666.40
AN1 Anagenics Limited 0.037 -5% -18% -38% $8,177,788.21
LDX Lumos Diagnostics 0.255 -6% -27% 0% $38,448,129.39
EPN Epsilon Healthcare 0.034 -6% -17% -77% $7,931,682.26
ATH Alterity Therap Ltd 0.016 -6% -16% -45% $38,509,993.25
ILA Island Pharma 0.15 -6% -21% -56% $6,486,949.20
NOX Noxopharm Limited 0.225 -6% -26% -61% $65,753,538.75
ACW Actinogen Medical 0.071 -7% -25% -26% $126,354,711.01
ALA Arovella Therapeutic 0.034 -7% -19% -11% $22,774,397.68
ZNO Zoono Group Ltd 0.195 -7% -19% -72% $33,282,341.00
MVP Medical Developments 2.66 -7% -25% -47% $199,654,159.60
NEU Neuren Pharmaceut. 3.45 -8% -12% 176% $443,399,179.52
CU6 Clarity Pharma 0.425 -8% -21% 0% $74,641,595.39
PAA Pharmaust Limited 0.084 -8% -9% -9% $26,620,640.17
GLH Global Health Ltd 0.23 -8% -19% -68% $13,029,446.41
MXC Mgc Pharmaceuticals 0.021 -9% -9% -57% $60,022,464.74
MDR Medadvisor Limited 0.2 -9% -23% -30% $76,157,987.80
S66 Star Combo 0.135 -10% -31% -47% $18,157,902.44
4DX 4Dmedical Limited 0.63 -10% -18% -48% $131,642,130.69
OSL Oncosil Medical 0.051 -11% -18% -35% $47,106,537.88
PSQ Pacific Smiles Grp 1.615 -11% -28% -35% $257,724,829.87
PNV Polynovo Limited 1.155 -11% 12% -56% $784,100,332.14
MX1 Micro-X Limited 0.16 -11% -18% -52% $73,832,682.56
NSB Neuroscientific 0.2 -11% -30% -32% $28,694,328.60
PYC PYC Therapeutics 0.071 -11% -25% -49% $225,845,753.31
AGH Althea Group 0.115 -12% -32% -70% $36,340,561.09
EYE Nova EYE Medical Ltd 0.22 -12% -15% -31% $32,027,554.02
AHK Ark Mines Limited 0.33 -12% -39% 871% $10,992,333.99
PGC Paragon Care Limited 0.31 -13% -19% 35% $202,944,505.37
PCK Painchek Ltd 0.034 -13% -17% -50% $40,744,972.76
RHT Resonance Health 0.081 -14% -33% -57% $37,329,010.46
TRU Truscreen 0.055 -15% -10% -24% $19,957,643.92
CMP Compumedics Limited 0.165 -18% -41% -59% $29,231,886.42
IHL Incannex Healthcare 0.4 -21% -6% 54% $530,785,963.22
JTL Jayex Technology Ltd 0.007 -22% -46% -79% $1,744,599.77
NYR Nyrada Inc. 0.155 -23% -18% -47% $24,181,348.50
1ST 1St Group Ltd 0.007 -30% -30% -63% $3,879,076.66
BPH BPH Energy Ltd 0.022 -41% -41% -76% $15,958,758.02

 

Analytica (ASX:ALT)

Analytica was the best healthcare performer in the last couple of weeks after announcing that its PeriCoach pelvic floor exercise system received patents grants in Europe and India.

In Europe, the patent was validated in Switzerland, France, Great Britain, Italy, Sweden, Turkey and Germany.

The invention has already been granted a patent in Australia and Japan.
 

Imugene (ASX:IMU)

Imugene said its Phase 1 clinical trial of cancer-killing virus CF33-hNIS VAXINIA has officially begun, with the dosing of the first patient.

Imugene and clinical partner City of Hope, a renowned cancer hospital in Los Angeles, said the Phase 1 trial will start by delivering a low dose of CF33-hNIS to cancer patients with metastatic or advanced solid tumours, who have had at least two prior standard of care treatments.

Imugene also released a letter to shareholders earlier this week, saying the company is as strong as it has ever been despite the share price falling by 53% this year.

In the letter, the company says it has not been immune to the recent turbulence in the market, but affirms that it’s fully funded with $100m in cash to weather the storm.
 

AnteoTech (ASX:ADO)

AnteoTech has successfully registered an updated EuGeni COVID-19 Rapid Antigen Test (RAT) in Europe.

Currently unavailable in Australia, the EuGeni is Aneteotech’s fast solution for rapid point-of-care testing.

With a small and portable benchtop design, it can be easily transported in the clinic and on the field for use by healthcare professionals.

The new European registration is for the same core SARS-CoV-2 Ag RAT registered in April of 2021, but now covers multiple use claims including combined nose and throat sampling.
 

Medibio (ASX:MEB)

Medibio confirmed the US FDA has confirmed the use of DSM-V Diagnostic Method for Medibio’s final depression validation trial.

Medibio’s clinical team proposed the International Neuropsychiatric Interview (MINI) as a diagnostic tool to satisfy the FDA’s request, whilst trying to minimise the burden of conduct for the validation trial.

The FDA has confirmed that the MINI can be used to support the trial clinician diagnosis.
 

Oneview Healthcare (ASX:ONE)

Oneview has this week signed a deal with BJC Health System to provide Oneview’s platform to 2,441 additional beds.

The agreement represents a 20% increase under an existing contract with BCJ, which now takes the number of beds using Oneview’s platform to 14,283.

Under this agreement, BJC will also be migrating to Oneview’s CXP Cloud Enterprise platform, and moving all existing deployments to Android hardware.